Regorafenib

Regorafenib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Diffuse Astrocytoma, IDH-Mutant、Glioblastoma, IDH-wildtype、Brain Metastases, Adult、Cervical Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Regorafenib 研究

• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

  II 期招募中法国NCT04116541

• FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907

• Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer

  III 期招募中中国NCT06992648

• Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

  II 期招募中美国NCT05113368

• ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

  II 期招募中美国NCT05366816

• STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

  II 期招募中意大利NCT07213570

• Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

  II 期招募中中国NCT05057052

• A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

  II 期招募中中国NCT06280105

• Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients

  I 期 / II 期招募中South KoreaNCT07096609

• KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

  II 期招募中中国NCT05985109

• A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

  I 期 / II 期招募中中国NCT07040228

• Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

  II 期招募中法国NCT06425133

• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  I 期 / II 期招募中美国NCT06047379

• Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

  I 期招募中中国NCT06363006

• Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

  II 期招募中中国NCT07559864

• A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

  II 期招募中日本NCT07689201

• Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

  II 期招募中RussiaNCT06949982

• A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

  I 期招募中中国NCT05155189

• A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

  II 期招募中中国NCT07328009

• TARGETed Therapy Drug MONITOring in DIGestive Oncology

  不适用招募中法国NCT05443087

• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

  II 期 / III 期招募中美国澳大利亚加拿大法国NCT03970447

• Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

  II 期招募中美国NCT07071961

• GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

  II 期招募中中国NCT06558773

• Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

  不适用招募中中国NCT05713994

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。